Department of Surgery, John Wayne Cancer Institute, Santa Monica, CA, USA.
Ann Surg Oncol. 2013 Aug;20(8):2576-81. doi: 10.1245/s10434-013-2924-7. Epub 2013 Mar 7.
There are few data on the long-term outcome of patients with microinvasive (T1mi) breast cancer. Moreover, predictors of lymph node involvement and the impact of multifocal microinvasion are not well understood.
Patients with T1mi cancer, defined as tumors ≤1 mm, surgically managed at our institute and who underwent axillary lymph node evaluation were identified. Specimen slides were independently reviewed. Multivariate analysis was used to identify factors predictive of lymph node involvement.
Forty-five patients with T1mi cancer were identified. Median patient age was 52 years, and median size of in situ disease was 4 cm. Nine tumors (20.0 %) had more than one focus of microinvasion. Lymph nodes metastasis were identified in 9 patients: 1 macrometastasis (2.2 %), 4 micrometastases (8.9 %), and 4 isolated tumor cells (8.9 %). Seven of 9 patients with lymph node involvement underwent adjuvant chemotherapy. Estrogen receptor-negative invasive disease was a significant predictor of lymph node metastasis by multivariable analysis (p < 0.02). There was also a trend toward lymph node involvement in patients with multifocal microinvasion compared to unifocal disease (33.3 vs. 16.7 %, respectively). At a median follow-up of 83 months, 3 patients (6.3 %) had disease recurrence (1 local, 1 distant, 1 local and distant). All patients with recurrence initially had tumor-free lymph nodes and only one focus of microinvasion.
Microinvasive breast cancer clearly has the ability to metastasize and recur, but in this series, only 2 % of patients with nodal macrometastasis. Only two patients experienced local recurrence, neither of whom had lymph node metastasis. The importance of identifying nodal micrometastasis in T1mi disease needs to be further explored.
关于微浸润(T1mi)乳腺癌患者的长期预后数据较少。此外,淋巴结受累的预测因素以及多灶微浸润的影响尚不清楚。
我们确定了在我们的研究所接受手术治疗且接受腋窝淋巴结评估的 T1mi 癌患者。独立审查了标本切片。使用多变量分析来确定预测淋巴结受累的因素。
确定了 45 例 T1mi 癌症患者。患者的中位年龄为 52 岁,原位疾病的中位大小为 4cm。9 个肿瘤(20.0%)有一个以上的微浸润病灶。9 例患者中有淋巴结转移:1 例巨转移(2.2%),4 例微转移(8.9%),4 例孤立肿瘤细胞(8.9%)。9 例淋巴结转移患者中有 7 例接受了辅助化疗。多变量分析显示,雌激素受体阴性浸润性疾病是淋巴结转移的显著预测因素(p<0.02)。与单灶病变相比,多灶微浸润患者的淋巴结受累也有趋势(分别为 33.3%和 16.7%)。在中位随访 83 个月时,3 例患者(6.3%)出现疾病复发(1 例局部,1 例远处,1 例局部和远处)。所有复发患者最初均无淋巴结肿瘤且仅存在一个微浸润病灶。
微浸润性乳腺癌显然有转移和复发的能力,但在本系列中,仅有 2%的淋巴结宏转移患者。仅有 2 例患者出现局部复发,均无淋巴结转移。在 T1mi 疾病中确定淋巴结微转移的重要性需要进一步探讨。